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ORIGINAL ARTICLE
Prostaglandin E2 promotes survival of naive UCB T cells via
the Wnt/b-catenin pathway and alters immune reconstitution
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The outcome of umbilical cord blood transplantation (UCBT) is compromised by low hematopoietic stem cell (HSC) doses leading to
prolonged time to engraftment, delayed immunological reconstitution and late memory T-cell skewing. Exposure of UCB to
dimethyl-prostaglandin E2 (dmPGE2) increases HSC in vivo. We determined that exposure of UCB T lymphocytes to dmPGE2
modiﬁed Wnt signaling resulting in T cell factor (TCF)-mediated transcription. Wnt signaling upregulated interleukin (IL)-7R and
IL-2Rb, resulting in enhanced survival mediated by the homeostatic cytokines IL-7 and IL-15. dmPGE2 also induced components of
the Wnt pathway and Wnt receptors, thereby priming UCB T cells to receive signals via Wnt ligands in vivo. We observed that the
Wnt transcription factor TCF7 and its target EOMES were elevated in the T cells of patients who received PGE2-treated UCBs.
Consistent with the role of Wnt/b-catenin signaling to induce and maintain naive, memory precursors and long-lived central
memory CD8
þ cells, these patients also had increased fractions of CD8
þCD45RO
-CD62L
þ plus CD8
þCD45RO
þCD62L
þ subsets
encompassing these T-cell populations. These effects of the PGE2/Wnt/b-catenin axis may have signiﬁcant implications for
harnessing immunity in the context of UCBT, where impaired immune reconstitution is associated with late memory T-cell skewing.
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INTRODUCTION
Allogeneic hematopoietic stem cell transplantation (HSCT) is the
only curative option for many patients with hematological
malignancies, congenital disorders and bone marrow failure.
Human leukocyte antigen-matched donor stem cells are preferred
in order to avoid rejection and graft versus host disease. However,
many patients do not have histocompatible donors.
1 Human
umbilical cord blood (UCB) stem cells have emerged as an option
for patients without suitable donors.
2 The use of UCB
transplantation (UCBT) has steadily increased since the ﬁrst
transplant in 1988 to more than 30000 recipients worldwide.
In the United States, UCBT accounts for almost 20% of all HSCT
annually.
3 As the absolute number of HSCs in the UCB unit is only
B10% of that present in traditional inoculum generated from
adult donors, to compensate for the low HSC numbers, dUCBT
(two umbilical cord blood units) are often used. However,
engraftment remains suboptimal resulting in more post-
transplant infectious complications than those observed in
matched adult donor transplant recipients and even death. For
these reasons, the development of methods and the identiﬁcation
of agents to increase UCB HSC homing, engraftment or HSC
number is of signiﬁcant therapeutic value.
It was previously demonstrated that PGE2 regulates vertebrate
HSC induction and engraftment.
4 PGE2 was identiﬁed through a
chemical genetic screen for modiﬁers of runx1 expression within
the zebraﬁsh aorta-gonadal-mesonephros. Short-term (ST) ex vivo
incubation with a stabilized derivative, 16,16-dimethyl-prostaglandin
E2 (dmPGE2), enhanced the formation of stem cells and zebraﬁsh
marrow recovery following irradiation injury. PGE2 signiﬁcantly
enhanced embryonic stem cell hematopoietic colony formation
and the frequency of both ST- and long-term repopulating
HSC in the mouse bone marrow. Limiting dilution competitive
transplantation analysis demonstrated a two- to fourfold increase in
HSC number after short ex vivo PGE2 exposure, without creating an
impact on multilineage hematopoietic differentiation or decreasing
serial transplantation and self-renewal potential.
4,5 PGE2 functions
through cyclic AMP (cAMP)-mediated regulation of the Wnt
signaling pathway to control HSC homing, proliferation and
survival.
5–7 On the basis of these ﬁndings, we performed a phase
Ib pilot clinical trial of dUCBT, using one untreated and one ex vivo
PGE2-treated UCB unit, to determine safety and engraftment
parameters (http://www.clinicaltrials.gov (NCT00890500)). We
demonstrated a signiﬁcant reduction in the median time to
engraftment compared with historic controls and skewing
toward long-term hematopoiesis derived from the PGE2-treated
UCB unit.
8
Although these previous studies investigated the effects of ST
ex vivo exposure of HSC to PGE2, the effect of this treatment on
the T cells present in the UCB has not been examined. PGE2
has immunomodulatory effects and, when continuously present
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www.nature.com/bcjduring culture, alters the differentiation program of T cells by
suppressing Th1 cell differentiation
9 and promoting development
of Treg.
10 PGE2 can also mediate Th17 differentiation.
11 Although
in other cell types PGE2 can induce direct Gsk3 phosphorylation
and inactivation, thereby leading to stabilization of b-catenin
and activation of T cell factor (TCF)/lymphoid enhancer-binding
factor (LEF)-mediated gene activation,
7,12 whether PGE2 can
modulate Wnt signaling in T cells has never been examined.
Wnt/b-catenin signaling promotes quiescence and improves
survival of CD4
þ Tc e l l s .
13,14 Wnt signaling controls the
generation of long-lived memory CD8
þ T cells and highly
potent stem cell memory CD8
þ T cells (TSCM), which display
naive immunophenotypic features and limited expansion but
potent antigen-speciﬁc function.
13,15,16 Such effects of PGE2 might
be of particular importance in UCBT where impaired immune
reconstitution is characterized by T-cell skewing to a late effector
CD8
þ phenotype.
17
Here we examined the effects of ST exposure of UCB T cells to
dmPGE2. We determined that transient ex vivo exposure of UCB
T cells to PGE2 modiﬁed the Wnt signaling cascade through
E-prostanoid (EP)2/EP4 receptors and cAMP-regulated phosphory-
lation of Gsk3, resulting in stabilization of b-catenin and
TCF/LEF-mediated transcription. As a consequence, PGE2 induced
an increase in interleukin (IL)-7Ra and IL-2Rb mRNA and protein
expression, enhanced survival mediated by the homeostatic
cytokines IL-7 and IL-15 and protected UCB T cells against
pro-apoptotic TCR-mediated signals. PGE2 also induced expres-
sion of Wnt pathway components and Wnt receptors, suggesting
that ex vivo PGE2 treatment of the UCB might prime UCB T cells to
receive Wnt/b-catenin signals in vivo after infusion into the UCBT
recipients. Consistent with this hypothesis, using as a paradigm
samples from four recipients of PGE2-treated UCBT recipients, we
detected elevated expression of the transcription factors TCF7 and
EOMES, which are regulated by Wnt signaling. Thus, besides
promoting HSC engraftment, ex vivo PGE2 treatment improves
survival and immunological properties of UCB T cells in a
Wnt-dependent manner.
MATERIALS AND METHODS
Cell isolation and culture
Mononuclear cells were isolated using Ficoll gradient centrifugation from
fresh research umbilical cord blood units obtained from the Dana-Farber
Cancer Institute (Boston, MA, USA). Umbilical cord blood units were
collected according to local Institutional Review Board-approved protocols.
Naive T cells were subsequently puriﬁed by negative selection using the
Human Naive T Cell Isolation Kit (Miltenyi Biotec, Bergisch Gladhach,
Germany). For T-cell activation and apoptosis induction, the tissue culture
plates were coated overnight with 5mg/ml of rabbit anti-mouse immuno-
globulins (Dako, Glostrup, Denmark) at 41C and the following day they were
washed three times and were incubated with anti-CD3 (0.7mg/ml; OKT3,
eBioscience, San Diego, CA, USA) for 1h at room temperature. After three
washes, cells were added to the plates and were incubated for the indicated
time periods. Where indicated, soluble human recombinant IL-7 and IL-15
were added at a ﬁnal concentration of 50ng/ml. Short, transient PGE2
treatment was carried out by culturing naive T cells (5 10
6 cells per ml) with
dmPGE2 (10mM)f o r2ha t3 71C. Cells were subsequently gently washed one
time with culture medium and used for the indicated studies.
cAMP measurement
Naive T cells were incubated with PGE2 for various time points (2–120min).
Cell pellets were collected and extraction was prepared by using
Amersham cAMP Biotrak EIA system (GE Healthcare, Little Chalfont, UK).
cAMP concentration in cell extracts was determined by enzyme
immunoassay according to the manufacturer’s instructions.
PKA assays
Naive T cells (1 10
6 cells per sample) were incubated with PGE2 (10mM)
for various intervals (5–60min). Subsequently, cell pellets were collected
and lysates were prepared and 0.02–1mg of crude protein per sample was
used. Protein kinase A (PKA) activity was determined using the PKA Kinase
Activity Kit (Enzo Life Sciences, Plymouth Meeting, PA, USA). Relative kinase
activity was measured using the formula provided by the manufacturer
(average absorbancesample average absorbanceblank)/quantity of crude
protein used per sample). At least three different samples per condition
were assessed and the experiment was repeated two times.
SDS-polyacrylamide gel electrophoresis and western blotting
Naive T cells were cultured with dmPGE2 for indicated time points and cell
lysates were prepared and quantiﬁed as previously described.
18 Equal
amounts of protein were analyzed by SDS-polyacrylamide gel
electrophoresis followed by immunoblot with antibodies speciﬁc for
phospho-AKT, total AKT, phospho-GSK3b and total GSK3b. All antibodies
were obtained from Cell Signaling Technologies (Danvers, MA, USA).
Where indicated, densitometric analysis was performed and quantiﬁcation
of integrated density was assessed using the ImageJ 1.41o software
(National Institutes of Health). Statistical signiﬁcance was deﬁned as a
P-valueo0.05 and was calculated with the InStat software (GraphPad
software, La Jolla, CA, USA).
Flow cytometry
The expression of b-catenin was assessed by intracellular staining with
allophycocyanin-conjugated antibody against b-catenin followed by ﬂow
cytometry analysis (eBioscience). For the determination of cell death, cells
were labeled with propidium iodide and Annexin-V (eBioscience), and
were analyzed by ﬂow cytometry (LSRII, Becton Dickinson, Franklin Lakes,
NJ, USA).
TCF/LEF reporter assay
Naive T cells were transfected with TCF/LEF Cignal Reporter Assay (Qiagen,
Valencia, CA, USA) by nucleofection (Lonza, Cologne, Germany). Four hours
after transfection, the cells were collected and cultured with PGE2 for 16
or 20h. The luciferase assay was performed by using Dual-Luciferase
Reporter Assay System (Promega, Madison, WI, USA) following the
manufacturer’s protocol for developing assay.
Real-time PCR
Naive T cells were cultured with PGE2 (10mM)a t3 7 1C for the indicated
time intervals. Where indicated, naive T cells were incubated with
6-bromoindirubin-30-oxime (BIO), a selective Gsk inhibitor or with
N-methylated BIO, an inactive analog of BIO (R&D Systems/TOCRIS,
Minneapolis, MN, USA) or with the older generation Gsk3 inhibitor
TWS119 (EMD4Biosciences, San Diego, CA, USA). Total RNA extraction was
prepared with the RNeasy Mini Kit from Qiagen according to the
manufacturer’s instructions. RNA was subjected to quantitative PCR (qPCR)
analysis for the target genes LEF1, JUN, EOMES, RUNX1, TCF7, CREM, c-MYC,
CTNNB1, FZD1, FZD9, LRP5, LRP6, DV1, DV3 and AXIN2. The FAM-conjugated
primers for all target genes as well as the TaqMan One-Step reverse
transcriptase-PCR Master Mix reagents (Life technologies, Grand Island, NY,
USA) and the VIC-TAMRA (Life technologies)-conjugated 18S RNA house-
keeping gene control primers were from Applied Biosystems/Roche,
Branchburg, NJ, USA. The reaction was performed in an AB 7000 qPCR
machine from Applied Biosystems. For assessment of EP receptors,
previously described primers
6 were obtained from IDT (Coralville, IA, USA).
Clinical trial
This research protocol was approved by the Institutional Review Board of
the Dana-Farber/Harvard Cancer Center. Written informed consent was
obtained from all patients for the correlative laboratory study of immune
reconstitution before enrollment and participation. The trial was prospec-
tively registered at http://www.clinicaltrials.gov (NCT00890500). Detailed
patient characteristics and clinical outcome of the entire clinical trial are
reported elsewhere.
8 Samples collected from patients who received one
untreated and one PGE2-treated UCB unit (PGE2-UCBT) were compared
with samples from patients who received two untreated UCB units
(control-UCBT).
Statistical analysis
In vitro assay, densitometry data and qPCR data were compared with
unpaired t-test. Analysis of variance was performed to compare the
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Blood Cancer Journal & 2014 Macmillan Publishers Limitedexpression levels of EOMES and TCF7 measured at days 0, 30, 60 and 100
after transplantation. A two-sided P-value of o0.05 was considered
statistically signiﬁcant.
RESULTS
PGE2 modulates Wnt/b-catenin signaling in UCB T cells
In adult T cells, PGE2 is known to signal via EP2 and EP4
receptors.
11 To determine whether UCB T cells were capable of
transmitting PGE2-mediated signals, we examined expression of
EP receptors. Naive UCB T cells expressed EP2 and more
prominently EP4 receptor, and lacked expression of EP1 and EP3
receptors (Figures 1a and b). dmPGE2 induced a robust elevation
of intracellular cAMP within 2min of incubation, which gradually
declined over 2h of treatment (Figure 1c). In other cell types,
via EP2 and EP4 receptors, PGE2 regulates intracellular phosphory-
lation through cAMP and the downstream effector kinases PKA
and PI3K/Akt.
12 To determine whether EP2 and EP4 receptors were
capable of transmitting signals in UCB T cells, we examined the
activation of PKA and PI3K/Akt pathways. dmPGE2 induced
activation of PKA (Figure 1d) and PI3K, leading to phosphorylation
of the PI3K target Akt (Figures 1e and f).
Figure 1. PGE2 induces activation of Wnt/b-catenin signaling. (a, b) Naive T cells isolated from UCB and expression of EP1, EP2, EP3 and EP4
genes was examined by qPCR (a). Data were normalized to b-actin. Results are representative of three independent assessments. Expression
of EP2 and EP4 receptors in naive UCB T cells was also analyzed by ﬂow cytometry (b). (c–j) Naive T cells isolated from UCB were incubated
with dmPGE2 (10mM) for indicated time intervals. Levels of intracellular cAMP were determined by enzyme immunoassay (c). The data shown
are representative of two performed experiments. (d) PKA activity was measured by enzyme-linked immunosorbent assay using PKA kinase
activity kit. Relative kinase activity was calculated as described in Materials and Methods. Data are means±s.d. of triplicate from one
experiment. PKA kinase activity was signiﬁcantly increased after incubation of T cells with PGE2 compared with that in untreated T cells
(*Po0.05). The data represent two independent experiments. (e, g) WT cells were incubated with PGE2 for the indicated time intervals, and
phosphorylation of Akt and GSK3b was assessed by immunoblot with phospho-speciﬁc antibodies. (i) T cells were treated for 15min with
PGE2 in the presence or absence of inhibitors for PKA (H-89) or PI3K (LY294002) and phosphorylation of GSK3b was examined. (f, h, j)
Densitometric analysis of the abundance of each indicated phosphorylated protein was normalized to that of total protein, and was expressed
as fold-change relative to mean values before stimulation (deﬁned as 1). Data are presented as the mean±s.e.m. *Po0.05, n¼4 experiments.
(k) Accumulation of b-catenin incubation of naive T cells with PGE2 was assessed by intracellular staining and ﬂow cytometry. Similar effects
were observed by the use of the Gsk3 inhibitor TWS119 (Supplementary Figure 1a). The data shown were generated from one experiment
and are representative of three independent experiments. (l) Naive T cells were transfected with TCF/LEF cignal reporter. After 4h, cells were
treated with 10mM PGE2 or vehicle alone. A dual-luciferase assay was performed 12 and 24h after incubation of T cells with PGE2, and reporter
activity values were expressed as arbitrary units using a Renilla reporter for internal normalization. Reporter activity was signiﬁcantly increased
in T cells that were treated with PGE2 (*Po0.05).
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EP2 and EP4 receptors in HEK cells can induce inactivating
phosphorylation of Gsk3 via PKA and PI3K/Akt,
7,12 leading to Gsk3
inactivation and stabilization of b-catenin. The levels of b-catenin
are tightly controlled by the destruction complex, consisting of
axin, GSK3, CK1 and allophycocyanin. In the absence of Wnt
signaling, b-catenin is phosphorylated at N-terminal residues by
GSK3b and targeted for ubiquitination/degradation.
19 In contrast,
C-terminal phosphorylation of b-catenin stabilizes the protein by
inhibiting destruction.
20 Destruction complex assembly can be
blocked by phosphorylation of Gsk3b at Ser9, which can be
mediated by PKA and Akt.
21 Consequently, b-catenin is
accumulated and translocated into the nucleus to regulate the
expression of Wnt target genes. As our studies showed that PGE2
induced activation of PKA and Akt in UCB T cells, we examined the
phosphorylation of GSK3b at Ser9. dmPGE2 induced rapid and
robust phosphorylation of GSK3b at Ser9 (Figures 1g and h).
To dissect whether PKA or Akt was responsible for the
phosphorylation of GSK3b, we used the PKA inhibitor H-89 and
the PI3K inhibitor LY294002. There was a reduction in PGE2-
mediated phosphorylation of GSK3b when the cells were treated
with either inhibitors, but inhibition was more prominent when
the PI3K inhibitor LY294002 was used (Figure 1j). Together with
the higher expression of EP4 than EP2 (Figures 1a and b), this
ﬁnding indicates that in UCB T cells PGE2 signals predominantly
via the EP4 receptor, which selectively activates the PI3K/Akt
pathway, in contrast to the EP2 receptor that preferentially
activates PKA.
12 As a result of the blockade of destruction complex
assembly by the inactivating phosphorylation of Gsk3b at Ser9,
expression of b-catenin was increased in UCB T cells treated with
dmPGE2 (Figure 1k).
The functional consequence of b-catenin accumulation is to bind
to TCF/LEF transcription factors, leading to transcriptional activation
of Wnt-responsive genes. To evaluate the potential of PGE2 in
modulating Wnt-mediated gene transcription in UCB T cells, we
performed transient transfections with the TCF/LEF-speciﬁc repor-
ter. Assessment of reporter activity showed a signiﬁcant increase of
luciferase activity in UCB T cells incubated with PGE2 compared
with vehicle control (Figure 1l). Of note, the increase of
Wnt-mediated transactivation induced by PGE2 in UCB T cells
was of moderate magnitude, similar to previous observations of
PGE2-mediated effects on Wnt-regulated transcriptional activity in
HSC.
7 Our data suggest that PGE2 modiﬁes Wnt/b-catenin
signaling in UCB T cells by increasing the accumulation of
b-catenin and promoting TCF/LEF-mediated transcriptional activity.
PGE2 induces Wnt target genes in UCB T cells
To determine whether our ﬁnding that dmPGE2-induced TCF/LEF-
mediated reporter activity in UCB T cells was biologically relevant,
we assessed expression of genes known to be regulated down-
stream of canonical Wnt signaling. Real-time quantitative reverse
transcriptase-PCR showed that the expression of LEF1, JUN, EOMES,
RUNX1 and TCF7, all of which have been identiﬁed as Wnt/b-
catenin-regulated targets,
7,15,16,22,23 were increased in UCB T cells
by dmPGE2 incubation (Figure 2a). PGE2 also upregulated
expression of CREM in UCB T cells, a gene previously identiﬁed
as a Wnt target induced by Wnt3A treatment of thymocytes.
22
In contrast, c-MYC, a Wnt target gene upregulated in human
colorectal cancer
24 and previously identiﬁed to be induced by
PGE2 in HSC,
7 was not upregulated in UCB T cells. Instead, PGE2
downregulated c-MYC expression in UCB T cells (Figure 2b),
suggesting that PGE2-mediated Wnt response genes are cell type-
speciﬁc. As in HSC, PGE2 also regulates expression of its own
receptors,
6 we examined whether PGE2 incubation might alter
expression of EP receptors in UCB T cells. PGE2 treatment had no
effect on EP2 (data not shown) but signiﬁcantly augmented
expression of EP4 (Figure 2a).
To verify that the effect of PGE2 on the upregulation of these
genes was mediated via transcriptional mechanisms downstream
of b-catenin, we used the iCRT3, -5 and -14 inhibitor, which blocks
b-catenin-responsive transcription by binding to b-catenin and
disrupting the interaction between b-catenin and TCF1.
25
Assessment of three representative Wnt target genes showed
that incubation of UCB T cells with iCRT inhibited induction of
LEF1, JUN and EOMES by dmPGE2 (Figure 2c). These results
provide evidence that PGE2 induced expression of these genes via
modulation of the b-catenin-mediated transcriptional activity in
UCB T cells.
PGE2 enhanced the anti-apoptotic effect of the homeostatic
cytokines IL-7 and IL-15
Previous studies showed that Wnt signaling in T cells prevents the
downregulation of IL-7Ra-chain (CD127), which occurs during
T-cell activation, and preserves high levels of IL-7Ra expres-
sion.
16,23 IL-2Rb chain (CD122), a shared subunit between IL-2 and
IL-15 receptors with an essential role in IL-15-mediated anti-
apoptotic function, is also upregulated via the Wnt/TCF pathway.
15
IL-7 and IL-15 promote survival and homeostasis of naive T cells,
development and survival of memory T cells, and enhance
immune reconstitution after HSCTs.
26–29 To evaluate whether
PGE2 pretreatment of UCB T cells might have an effect on T-cell
survival mediated via these homeostatic cytokines, ﬁrst we
examined the effects of dmPGE2 on the expression of IL-7Ra
and IL-2Rb. After ST treatment with dmPGE2 or vehicle control,
UCB T cells were stimulated via TCR/CD3 and expression of IL-7Ra
and IL-2Rb was assessed. PGE2 treatment signiﬁcantly diminished
the downregulation of IL-7Ra induced by TCR stimulation
(Figure 3a). Although no apparent difference in the expression
of IL-15Ra was observed, IL-2Rb was increased (Figure 3a).
Notably, both IL-7Ra and IL-2Rb mRNA were induced by PGE2
treatment alone and their induction was abrogated by incubation
of T cells with iCRT (Figure 3b), indicating that PGE2 induced
expression of these genes by modulating b-catenin-mediated
transcriptional activity. To further investigate whether IL-7Ra and
IL-2Rb were Wnt target genes, we used BIO a speciﬁc inhibitor of
Gsk3b.
30 Bio-acetoxime treatment resulted in robust increase of
both IL-7Ra and IL-2Rb mRNA. In contrast, treatment with
N-methylated BIO, an inactive analog of BIO-acetoxime did not
alter expression of either IL-7Ra or IL-2Rb mRNA (Figure 3b).
These results provide evidence that IL-7Ra and IL-2Rb are Wnt
target genes and their expression is upregulated by PGE2 in UCB T
cells. As a consequence of this effect, when combined with
TCR-mediated stimulation, PGE2 prevented the decrease of
IL-7Ra mRNA and augmented the upregulation of IL-2Rb mRNA
mediated by TCR signals (Figure 3c).
To determine the biological implications of these ﬁndings, we
examined whether PGE2 might enhance the pro-survival effects of
IL-7 and IL-15 and protect UCB T cells, which are highly prone to
TCR-mediated apoptosis.
31 After prior treatment either with
dmPGE2 or vehicle control, UCB T cells were cultured with plate-
bound OKT3 monoclonal antibody and apoptosis was assessed by
Annexin-V and propidium iodide staining. TCR-mediated
stimulation of control-treated T cells resulted in a signiﬁcant
degree of apoptosis (Figure 3d). Culture of PGE2-treated T cells
under the same conditions induced a slight but reproducible
decrease of apoptosis, which did not reach statistical signiﬁcance.
Addition of IL-7 or IL-15 during TCR-mediated stimulation
improved survival in both control- and PGE2-treated UCB T cells.
However, during culture with either IL-7 or IL-15, apoptosis of
PGE2-treated UCB T cells was signiﬁcantly decreased as compared
with control-treated UCB T cells (Figure 3d).
To further analyze the effects of PGE2 on the apoptotic
machinery activated by TCR/CD3, we evaluated the levels
of active, cleaved caspase-3. TCR-mediated stimulation of
Effects of PGE2/Wnt/b-catenin pathway on UCB T cells
LL iet al
4
Blood Cancer Journal & 2014 Macmillan Publishers Limitedcontrol-treated T cells resulted in caspase-3 activation that was
only slightly reduced by PGE2 pretreatment (Figure 3e). Addition
of IL-7 or IL-15 during TCR-mediated stimulation reduced caspase-3
activation in both control-treated and PGE2-treated UCB T cells.
Under these conditions, there was a 50% decrease of caspase-3-
positive fractions in PGE2-pretreated T cells compared with control-
treated UCB T cells (Figure 3e). These results indicate that PGE2
pretreatment protects UCB T cells under pro-apoptotic conditions
and suggest that T cells of the PGE2-treated UCB may display
survival advantage in vivo after infusion to the UCBT recipients.
PGE2 induces components of the Wnt/b-catenin pathway and Wnt
receptors in UCB T cells
The Wnt pathway regulates not only the expression of Wnt target
genes but also the expression of Wnt pathway signaling
components and Wnt receptors.
15,22 As our studies showed that
PGE2 induced modulation of Wnt/b-catenin signaling and gene
transcription in UCB T cells, we examined whether genes
encoding for components of the Wnt pathway and/or Wnt
receptors were also affected. Using real-time qPCR, we
determined that PGE2 induced a signiﬁcant increase of the Wnt
pathway component CTNNB1, the Wnt receptors FZD1, FZD9 and
the co-receptor LRP6 (Figure 4). PGE2 also upregulated DVL
molecules, which connect the Fzd-Lrp receptor and the b-catenin
destruction complexes. These molecular effects were speciﬁc and
selective because the members of these gene families were not
globally affected by PGE2 in UCB T cells (Figure 4). These results
show that short transient incubation of UCB T cells with PGE2
induces regulatory components of the Wnt pathway and Wnt
receptors and suggest that upon ex vivo PGE2 treatment, UCB
T cells might be primed to receive enhanced Wnt/b-catenin-
mediated signaling through Wnt ligands in vivo after infusion to
the UCBT recipients.
Figure 2. PGE2 regulates expression of Wnt/b-catenin target genes. (a) Naive T cells isolated from UCB were cultured with dmPGE2 (10mM)f o r
the indicated time intervals and RNA was isolated and expression of LEF, JUN, EOMES, RUNX1 and TCF7 was assessed by quantitative reverse
transcriptase-PCR. (b) Assessment of CREM, c-MYC and EP4 mRNA was performed at isolation and after 5h of culture with dmPGE2.
The expression of the indicated genes was signiﬁcantly altered after PGE2 incubation, compared with untreated T cells (*Po0.05). No changes
in the expression in any of the tested genes were detected upon culture with vehicle alone for the same time intervals (data not shown).
The effects of the Gsk3 inhibitor TWS119 on two representative Wnt target genes were tested in parallel (Supplementary Figures 1b). (c) After
culture for 5h with PGE2 in the presence of vehicle (PGE2) or iCRT (60mg/ml) (PGE2þiCRT), expression of LEF, JUN and EOMES was assessed as
in a. Data are presented as mean±s.d. The expression of the indicated genes was signiﬁcantly reduced after addition of iCRT compared with
incubation with PGE2 with vehicle alone (*Po0.05). The data represent two independent experiments.
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altered fractions of CD8
þ T-cell subsets in PGE2-UCBT recipients
As our in vitro studies suggested that transient ex vivo incubation
with PGE2 might prime UCB T cells to receive enhanced signals
through Wnt ligands, we sought to determine whether evidence
of ampliﬁed Wnt signaling might be detectable in vivo. We used as
a paradigm T cells from patients from a phase Ib pilot clinical trial
of dUCBT who received one untreated and one ex vivo PGE2-
treated UCB unit (thereafter named recipients of PGE2-UCBT).
These patients developed complete T-cell chimerism from the
PGE2-treated UCB unit as early as day þ13.
8 T cells transferred
with the graft are the dominant source of circulating T
lymphocytes before thymic regeneration, which occurs after 3
months from UCBT.
17,32 Thus, in recipients of PGE2-UCBT, T cells of
the UCB unit that was exposed to PGE2 ex vivo consist the
dominant circulating T-cell population in the ﬁrst 3 months
after UCBT. Using real-time qPCR, we assessed expression of
Wnt-regulated hallmark transcripts TCF7 and EOMES in the
peripheral blood lymphocytes of UCBT recipients. As compared
with recipients of control-UCBT, recipients of PGE2-UCBT had
increased expression of TCF7 and EOMES at all the time points
tested (Figures 5a and b). These differences were unlikely to be
due to random individual variability because assessment of these
genes in healthy controls showed comparable expression (data
not shown). We performed analysis of variance on TCF7 and
EOMES with repeated measures at days 0 (pre-transplant), 30, 60
and 100, and we found that both TCF7 and EOMES were
signiﬁcantly higher in the PGE2-UCBT group (Po0.001) compared
with the control-UCBT group. The interaction terms between TCF7
or EOMES and days were also signiﬁcant (Po0.001) indicating that
Figure 3. PGE2 incubation results in increased expression of IL-7Ra and IL-2Rb and enhances the anti-apoptotic effects mediated by IL-7 and
IL-15 in UCB T cells. (a) Naive T cells treated with PGE2 or vehicle control for 2h were stimulated with plate-bound anti-CD3 (OKT3, 0.7mg/ml).
Twenty-four hours after the initiation of culture, expression of IL-7Ra, IL-15Ra and IL-2Rb was examined by ﬂow cytometry. Naive T cells were
cultured with either PGE2, PGE2 plus iCRT3, BIO or N-methylated BIO (MeBIO) for 2h (b) or with OKT3 in the presence of vehicle or PGE2 (c),
and expression of IL7Ra and IL-2Rb mRNA was determined by qPCR. Data are means±s.d. of duplicates. PGE2 signiﬁcantly upregulated
expression of IL-7Ra and IL-2Rb mRNA (*Po0.05, n¼2). (d, e) Naive UCB T cells were treated with either vehicle or PGE2 for 2h and were
subsequently stimulated with plate-bound anti-CD3 (OKT3, 0.7mg/ml) in the presence of IL-7 (50ng/ml) or IL-15 (50ng/ml) or absence of these
cytokines. After 24h of culture, the cells were collected and apoptosis was measured by Annexin-V staining d. Data are means±s.d. of two
independent experiments. Addition of IL-7 or IL-15 signiﬁcantly prevented TCR-mediated apoptosis of control-treated cells (
þPo0.05) or
PGE2-treated UCB T cells (
oPo0.05) compared with the relevant cultures without addition of these cytokines. During culture with either IL-7 or
IL-15, treatment with PGE2 signiﬁcantly reduced apoptosis compared with control-treated UCB T cells (*Po0.05). (e) Activated caspase-3 was
detected by staining cells with antibody speciﬁcally against cleaved caspase-3 followed by ﬂow cytometry analysis. Treatment of naive T cells
with PGE2 for 2h did not induce an inhibitory effect on T-cell proliferation or cytokine production upon subsequent stimulation
(Supplementary Figures 2a and b).
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over time, whereas this pattern was not seen in the control-UCBT
group.
A major defect contributing to the impaired immune reconsti-
tution after UCBT is the paucity of naive and central memory
CD8
þ T cells and the skewing to a late effector CD8
þ T-cell
subset.
17 This mechanism is a signiﬁcant cause of the impaired
immune function after UCBT because naive and the central
memory CD8
þ subsets are more potent regulators of protective
immunity than effector memory and effector CD8
þ cells.
33–35
Wnt/b-catenin signaling arrests CD8
þ T-effector cell terminal
differentiation, preserves naive T cells and induces the generation
and maintenance of central memory CD8
þ T cells.
13,15,16,23,36,37
Notably, SELL encoding for CD62L, which is expressed speciﬁcally
in naive and central memory CD8
þ T cells, is a direct target of the
Wnt transcription factor TCF1 (encoded by TCF7).
15 For these
reasons, we examined whether ex vivo PGE2 treatment of T cells
present in the UCB might prevent the terminal differentiation of
CD8
þ T cells induced in vivo after UCBT
17 and might augment
the naive and central memory CD8
þ T-cell fractions. We used
the established combination of CD45RO and CD62L markers
to identify naive (CD45RO
 CD62L
þ), central memory
(CD45RO
þCD62L
þ), effector memory (CD45RO
þCD62L
 ) and
late effector memory (CD45RO
 CD62L
 ) CD8
þ T-cell subsets.
We analyzed proportional distribution of these CD8
þ T-cell
fractions before transplantation and during the ﬁrst 100 days
after UCBT. At baseline, the CD8
þ compartment was characterized
by low levels of naive and paucity of central memory cell fractions
in both groups (Figure 5c). After UCBT, in control recipients, the
bulk proportion of CD8
þ T cells expressed predominantly markers
of effector memory and late effector differentiation, and
suppressed CD62L
þ subsets, encompassing CD8
þCD45RO
 
CD62L
þ and CD8
þCD45RO
þCD62L
þ cells (Figures 5c and d),
consistent with previous observations.
17 In contrast, PGE2-UCBT
recipients had higher CD8
þCD45RO
 CD62L
þ and CD8
þ
CD45RO
þCD62L
þ cell fractions (Figures 5c and d). Although this
difference did not reach statistical signiﬁcance because of the
small sample size (P¼0.07), there was a clear trend for a higher
proportion of the combined CD8
þCD45RO
 CD62L
þ plus CD8
þ
CD45RO
þCD62L
þ fractions in PGE2-UCBT recipients (Figure 5d).
These ﬁndings do not intend to make clinically relevant
conclusions because our study was not designed to address
clinically relevant questions related to Wnt-mediated effects
in vivo. However, these ﬁndings can serve as a paradigm, which
supports the hypothesis that short, transient exposure to PGE2
may alter the properties of UCB T cells after UCBT in a Wnt-
dependent manner.
DISCUSSION
Our studies showed that short incubation with dmPGE2 altered
the molecular and functional properties of human UCB T cells by
inducing a robust increase of cAMP via EP2 and EP4 receptors and
activating a cascade of signaling events, which resulted in
inactivating phosphorylation of GSK3b, stabilization of b-catenin
and TCF/LEF-mediated gene expression. PGE2 incubation induced
increased expression of IL-7Ra (CD127) and IL-2Rb (CD122)
resulting in enhanced anti-apoptotic effects of IL-7 and IL-15
cytokines and a survival advantage of PGE2-treated UCB T cells
under pro-apoptotic conditions. PGE2 also upregulated Wnt
pathway components and Wnt receptors, suggesting that
ex vivo treatment with PGE2 could prime UCB T cells to receive
Wnt-mediated signaling in vivo after transfer to the UCBT
recipients.
Wnt signaling in mouse and human T cells limits effector T-cell
differentiation and induces the generation of CD8
þ TSCM cells,
which display immunophenotypic features of naive T cells and
‘stemness’ properties, characterized by quiescence, self-renewal
and multipotency. These cells give rise to central memory, effector
memory and effector CD8
þ T cells in response to antigen
re-exposure and mediate protective immunity.
16,38 Studies in
mouse models have shown that Wnt and its downstream target
TCF7 have a mandatory role for the generation and maintenance
of long-lived protective memory CD8
þ cells, whereas in the
absence of Wnt/TCF7 signals there is a dominance of short-lived
terminally differentiated effector CD8
þ T cells that fail to mount
protective immune responses.
13,15,37,39 Samples from our pilot
clinical trial that was designed to study safety and engraftment
Figure 4. PGE2 regulates expression of the Wnt-b/catenin pathway components in UCB T cells. Naive UCB T cells were cultured with dmPGE2
for 2h and expression of the indicated genes was assessed by qPCR. Data are means±s.d. and represent two independent experiments
(*Po0.05). AXIN2, a universal Wnt target gene pathway,
52 was used to verify Wnt pathway signaling. Increase of AXIN2 is shown at 5h of
culture because shorter time intervals of incubation resulted in only slight increases that did not reach statistical signiﬁcance.
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supportive translational paradigm to our in vitro studies on the
molecular and biochemical effects of PGE2 on UCB T cells.
Consistent with our in vitro data that PGE2 induced components
of the Wnt pathway and Wnt receptors, our correlative studies
indicated that PGE2 enhanced and sustained the activation of
the Wnt/b-catenin/TCF axis in the lymphocytes of PGE2-UCBT
recipients, as determined by the increase in the expression of the
Wnt target genes TCF7 and EOMES. These ﬁndings are consistent
with the conclusion that PGE2 primed T cells to receive enhanced
Wnt-mediated signals through Wnt ligands in vivo. Whereas the
identity and source of Wnt ligands that signal to T cells in vivo
remain to be elucidated, it has been shown that macrophages
and in vitro-differentiated dendritic cells can produce Wnt7b
and Wnt5a, respectively,
40,41 and that multiple Wnt transcripts
including Wnt1, 2B, 4, 5A and 8B are detected in vascular
endothelial cells.
42 Thus, PGE2-treated T cells expressing high
levels of Wnt receptors may be capable of repeatedly receiving
signals mediated via Wnt ligands during circulation and encounter
with dendritic cells. This hypothesis can explain the persistent
elevation of TCF7 and EOMES observed in the T cells of PGE2-UCBT
recipients. Interestingly, PGE2-UCBT recipients had higher factions
of CD8
þCD45RO
 CD62L
þ and CD8
þCD45RO
þCD62L
þ T cells.
Although these two cell subsets were traditionally considered to
represent naive and central memory CD8
þ T cells, respectively,
it was recently determined that the newly identiﬁed TSCM
population shares immunophenotypic properties with both
these cell subsets.
38 Thus, these cell populations in PGE2-UCBT
recipients may also contain TSCM CD8
þ cells.
TSCM cells were initially described as a very small fraction
within the CD45RO
 CD45RA
þCCR7
þCD62L
þIL-7Ra
þ naive cell
population, which is characterized by elevated expression
of IL-2Rb (CD122) and CD95.
38 In spite of their naive-like
immunophenotype, TSCM cells show functional properties of
memory T cells and can mount potent responses against viral
and tumor antigens.
16,38 It was recently reported that besides
CD45RA and other surface markers of naive cells including CD62L,
CCR7 and IL7Ra,T SCM cells also express CD45RO and represent a
distinct CD8
þ T-cell subset, intermediate between naive and
central memory cells.
43 Although our pilot correlative studies in
Figure 5. Increased expression of functional central memory genes and altered CD8þ T-cell reconstitution in PGE2-UCBT recipients.
(a, b) Peripheral blood T lymphocytes from four control-UCBT recipients (blue diamonds) and four PGE2-UCBT recipients (red closed circles)
were analyzed for expression of TCF7 and EOMES by real-time quantitative reverse transcriptase-PCR. Relative change of gene expression was
calculated with respect to levels on day 0, considered as 100 (100%). We performed analysis of variance on log10-transformed TCF7 and EOMES
with repeated measures at days 0 (pre-transplantation), 30, 60 and 100, and we found that both EOMES and TCF7 were signiﬁcantly higher in
the PGE2-UCBT group (Po0.001) compared with the control-UCBT group. A similar pattern was observed in ﬁve additional patients in the
PGE2-UCBT group but because samples were not available for all the time points of follow-up, these patients were not included in the plots.
(c) The relative proportions of the four indicated CD8
þ T-cell subsets were assessed using three-color ﬂow cytometry. (d) The combined
CD8
þCD45RO
 CD62L
þ plus CD8
þCD45RO
þCD62L
þ T-cell fractions, encompassing naive, memory precursors and central memory cells,
displayed distinct kinetics of reconstitution and a clear trend for higher values in PGE2-UCBT recipients versus control-UCBT recipients
(P¼0.07). Results represent mean values of 9 control-UCBT recipients and 12 PGE2-UCBT recipients.
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TSCM cells, the molecular and immunophenotype properties
induced by PGE2 in naive UCB T cells in vitro resemble these
features of TSCM cells. We determined that PGE2 upregulated
IL-7Ra and IL-2Rb and enhanced IL-7- and IL-15-mediated effects
in UCB T cells. As besides Wnt signaling,
16,38 IL-7 and IL-15 can also
instruct the generation of TSCM cells,
43 our ﬁndings suggest that
ex vivo PGE2 treatment of UCB T cells might promote the
generation of TSCM cells in vivo by enhancing Wnt/b-catenin-
mediated signals and IL-7/IL-15-mediated signals. Thus, PGE2
might promote the formation and maintenance of TSCM, similar to
HSCs. Future studies will focus speciﬁcally on the effects of PGE2
on the quantitative and qualitative proﬁles of TSCM cells.
Similar to previously identiﬁed effects of PGE2 on CD34
þ HSC,
in UCB T cells PGE2 upregulated expression of RUNX1, a molecule
with a critical role in T-cell polarization and functional differentia-
tion. In the presence of Foxp3, Runx1 has an indispensable role in
the generation and function of Treg, whereas in the presence of
RORgt, Runx1 is required for the generation of Th17 cells.
44 This
consequence of PGE2-mediated signals might have signiﬁcant
implications on the in vivo differentiation program and the
plasticity of UCB T cells, which in the context of distinct
microenvironmental factors might be capable of undergoing
differentiation to Treg or to Th17 cells.
45,46 This ﬁnding might also
account for the divergent previous reports regarding the ability of
PGE2 to induce generation of Treg and Th17 cells.
10,11 Through
this mechanism, PGE2 might also instruct the differentiation of
IL-17-producing CD8
þ T cells, which have potent antitumor
properties.
47 Of note, our studies showed that short incubation
with PGE2 upregulated EP4 suggesting that ex vivo PGE2-treated
T cells are primed to receive enhanced in vivo signaling mediated
by PGE2, which is elevated after HSCT.
48
Our studies showed that PGE2 treatment upregulated the
expression of IL-2Rb (CD122), prevented the downregulation of
IL-7Ra (CD127) in response to TCR stimulation and enhanced the
anti-apoptotic effects of IL-7 and IL-15 upon TCR-mediated
apoptosis of UCB T cells. Serum IL-7 and IL-15 levels increase
from the baseline upon lymphopenia induced by conditioning
chemotherapy, promote T-cell survival and enhance immune
reconstitution after HSCT.
29 Thus, PGE2-treated UCB may have
survival advantage over untreated T cells in the presence of IL-7
and IL-15 after infusion to the UCBT recipient. Consistent with this
hypothesis, in our phase I clinical trial, complete T-cell chimerism
from PGE2-treated UCB was detected as early as day þ13.
8
Although single-donor chimerism is generally documented within
1–3 months after double UCBT, the mechanisms of UCB unit
dominance have not yet been fully unraveled.
49,50 Recently, it was
determined that UCB unit dominance in leukocyte subsets is
established within 18 days after transplantation and that
chimerism in CD4
þ, CD8
þ and natural killer T cells at day þ11
is predictive of the ultimate UCB unit dominance.
51 It is tempting
to speculate that PGE2-mediated survival advantage of UCB T cells
might be responsible for the early T-cell chimerism observed in
PGE2-UCBT recipients. This event might also have an
indispensable role in the PGE2-UCB unit dominance, which is
further promoted by the effects of PGE2 on the homing and
survival of long-term repopulating HSC.
6,7 Further studies are
required to determine how PGE2 treatment individually affects
CD4
þ, CD8
þ and natural killer T-cell subsets and whether it alters
their alloreactive and cytolytic properties, which might be
involved in a presumed alloreactive graft versus graft rejection
in vivo.
51
By improving HSC engraftment while favoring the dominance
of naive plus central memory CD8
þ T cells, which provide
protective immunity,
33–35 ex vivo PGE2 treatment of the UCB
might improve the outcome of UCBT, where delayed engraftment
and impaired immunity due to late effector T-cell skewing
17 are
serious causes of morbidity and mortality. These effects of the
PGE2/Wnt/b-catenin axis in human T cells may also have
signiﬁcant implications for harnessing immune memory in the
context of tumor-speciﬁc and pathogen-speciﬁc immunity.
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